LB Pharmaceuticals Inc. has 19 Schedule 13D or 13G filings on record since 2025-09-18. 9 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Deep Track Capital, LP | 11.7% | 3,352,804 | SCHEDULE 13D/A, 2026-02-10 | 2025-02-06 |
| RA Capital Management, L.P. | 8.7% | 2,208,604 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Commodore Capital LP | 6.8% | 1,972,369 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | 1,411,681 | SCHEDULE 13D, 2025-09-25 | 2025-09-12 |
| BlackRock, Inc. | 6.3% | 1,796,543 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| Jpmorgan Chase & Co | 5.2% | 1,497,293 | SCHEDULE 13G, 2026-07-16 | 2026-06-30 |
| TCG Crossover GP II, LLC | 5% | 1,447,310 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Trails Edge Capital Partners, LP | 5% | 1,268,265 | SCHEDULE 13G, 2025-12-31 | 2025-12-24 |
| Caligan Partners LP | 5% | 1,438,070 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| BlackRock Portfolio Management LLC | 3.8% | 961,158 | SCHEDULE 13G/A, 2026-01-21 | 2025-12-31 |
Purpose of Transaction (Item 4)
Deep Track Capital, LP
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On February 4, 2026, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors") pursuant to which the Issuer, in a private placement (the "Private Placement"), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the "Shares") of the Issuer's Common Stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,417,107 shares of Common Stock (such shares issuable upon exercise of the Pre-Funded Warrants, the "Warrant Shares", and together with the Shares and the Pre-Funded Warrants, the "Securities"). Each Share was offered and sold at a purchase price of $21.17 before deducting underwriting discounts and commissions and each Pre-Funded Warrant was offered and sold at a purchase price of $21.1699, which is equal to the purchase price per Share less the $0.0001 exercise price of each Pre-Funded Warrant, before deducting underwriting discounts and commissions. Each of Deep Track Biotechnology Master Fund, Ltd ("DTBMF") and Deep Track Special Opportunities Fund, LP ("DTSOF") purchased 378,444 and 93,925 Pre-Funded Warrants, respectively, in the Private Placement. The Private Placement closed on February 6, 2026. Each Pre-Funded Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. The Pre-Funded Warrants are exercisable immediately and may be exercised …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-02-10; the filing has the rest
Pontifax Management 4 G.P. (2015) Ltd.
The Reporting Persons acquired the securities reported herein for investment purposes, subject to the following: The Reporting Persons intend to review on a continuing basis the investments in the Issuer by the Reporting Persons. The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the Reporting Persons' investment in the Issuer's securities. Depending on various factors, including, without limitation, the price and availability of the Issuer's securities, subsequent developments affecting the Issuer, the Issuer's business and the Issuer's prospects, other investment and business opportunities available to such Reporting Persons, general industry and economic conditions, the securities markets in general, tax considerations and other factors deemed relevant by such Reporting Persons, the Reporting Persons may seek to sell or otherwise dispose some or all of the Issuer's securities or any derivatives thereof (which may include distributing some or all of such securities to such Reporting Person's respective partners or beneficiaries, as applicable) from time to time, and/or may seek to acquire additional securities of the Issuer or any derivatives thereof (which may include rights or securities exercisable or convertible into securities of the Issuer) from time to time, in each case, in open market or private transactions, block sales or …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-25; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | TCG Crossover GP II, LLC | 7.8% | SCHEDULE 13G |
| 2025-09-18 | Commodore Capital LP | 5.5% | SCHEDULE 13G |
| 2025-09-19 | Deep Track Capital, LP | 14.9% | SCHEDULE 13D |
| 2025-09-19 | RA Capital Management, L.P. | 7.5% | SCHEDULE 13G |
| 2025-09-25 | Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | SCHEDULE 13D |
| 2025-10-17 | BlackRock Portfolio Management LLC | 5.9% | SCHEDULE 13G |
| 2025-12-31 | Trails Edge Capital Partners, LP | 5% | SCHEDULE 13G |
| 2026-01-21 | Jpmorgan Chase & Co. | 6.3% | SCHEDULE 13G |
| 2026-01-21 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2026-01-21 | BlackRock Portfolio Management LLC | 3.8% | SCHEDULE 13G/A |
| 2026-02-10 | Deep Track Capital, LP | 11.7% | SCHEDULE 13D/A |
| 2026-02-17 | RA Capital Management, L.P. | 8.7% | SCHEDULE 13G/A |
| 2026-05-13 | Jpmorgan Chase & Co | 4.9% | SCHEDULE 13G/A |
| 2026-05-15 | TCG Crossover GP II, LLC | 6.4% | SCHEDULE 13G/A |
| 2026-05-15 | Caligan Partners LP | 5% | SCHEDULE 13G |
| 2026-05-15 | Commodore Capital LP | 6.8% | SCHEDULE 13G/A |
| 2026-07-16 | Jpmorgan Chase & Co | 5.2% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 6.3% | SCHEDULE 13G/A |
| 2026-08-14 | TCG Crossover GP II, LLC | 5% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for LB Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.